Compare SYSCO Corporation (SYY) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SYSCO Corporation vs State Street SPDR S&P Biotech ETF — how do they compare? SYSCO Corporation trades at $78.14 (market cap $38.47B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: SYSCO Corporation is far larger — about 3.8× State Street SPDR S&P Biotech ETF's market cap, and SYSCO Corporation pays a 2.81% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold SYSCO Corporation for 77 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| SYY | XBI | |
|---|---|---|
Market Cap | $38.47B | $10.11B |
Volume | 4,808,465 | 12,903,266 |
Sector | Consumer Staples | Broad Market / Factor |
52-Week High | $91.16 | $169.55 |
52-Week Low | $69.30 | $104.99 |
Typical Hold Time | 77 Days | 38 Days |
Enterprise Value | $51.65B | — |
Dividend Yield | 2.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sysco (SYY) trades at $78.20, up 1.84% with neutral technical signals and strong institutional support. The stock shows solid fundamentals with $81.37B revenue, 2.08% net margin, and attractive valuation at P/E 21.37 and P/S 0.44. Recent corporate actions include a $0.55 dividend and $1B stock offering, while the company reaffirmed fiscal 2027 guidance and launched a $500M AI efficiency program.
Sysco presents a balanced investment case with 60% analyst buy ratings and $85.75 consensus target offering 9.6% upside. The food distribution leader benefits from consistent revenue growth and AI-driven efficiency initiatives, though margin pressure and competitive threats warrant monitoring. Current valuation appears reasonable given the company's market position and growth trajectory.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive catalysts from biotech breakthroughs. Recent news highlights XBI's 76% rally over the past year and ongoing M&A activity driving sector optimism.
Outlook remains cautiously optimistic with potential upside from cancer vaccine developments and sector consolidation, though high volatility and expense ratios relative to broader healthcare ETFs present risks. The ETF's modified equal-weight structure offers diversified exposure to 150+ biotech names, benefiting from improved capital access and clinical trial catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About SYSCO Corporation
Sysco is the largest U.S. food-service distributor, boasting 17% market share of the highly fragmented food-service distribution industry. Sysco distributes over 400,000 food and nonfood products to restaurants (63% of revenue), healthcare facilities (8%), education and government buildings (8%), travel and leisure (7%), and other locations (14%) where individuals consume away-from-home meals. In fiscal 2022, 82% of the firm's revenue was U.S.-based, with 7% from Canada, 4% from the U.K., 2% from France, and 4% other.
Read more on SYY →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
